A randomized, double-blind, placebo-controlled, single- and multiple-dose ascending safety, tolerability, and pharmacokinetics study of ZHB103 injection in healthy subjects
Latest Information Update: 06 Aug 2025
At a glance
- Drugs ZHB 103 (Primary)
- Indications Ischaemic stroke
- Focus Adverse reactions
Most Recent Events
- 30 Jul 2025 New trial record